# 該公司必須至少涵蓋這5項評級中的4項，才能進行計算。

*biotech · news · 2025-10-17 · MarketScreener*

## Key points

- Trader超級評級以4個月內的每股盈餘修正作為主要輸入。
- Investor綜合評級使用計算期間為1年的每股盈餘修正。
- Global綜合評級要求至少涵蓋5項特定標準中的4項才能計算。
- Quality綜合評級要求至少涵蓋3個輸入類別中的2個才能計算。

Trader This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions. Investor This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions. Global This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions. Quality This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.

[Read the full story on MarketScreener](https://www.marketscreener.com/news/hansoh-pharma-units-sign-up-to-1-4-billion-licensing-deal-with-roche-for-cancer-drug-ce7d5adcde8dfe22)

---

Canonical: https://newsio.io/zh-TW/n/ab652182-c924-4abb-9813-ef5dff01b888/54
Summarized by Newsio from MarketScreener. https://newsio.io/how-it-works